Neurológia pre prax 5/2009

New drugs era in treating multiple sclerosis

Contemporary therapeutic approaches for treating of Multiple sclerosis have their limitation. The efficacy is not 100 % and long lasting invasive application have troubles, which lead to less therapeutic effect. This is the reason for developing new ways, schemes and methods. Some of them were blind and did not fulfil expectations. Other new medications are very effective, but have serious adverse events. The article introduces new medications, which came through all phases of clinical testing to the registration or phase III studies have been just ending. This involves five oral disease-modifying agents and monoclonal antibodies group which represents another big expectation.

Keywords: multiple sclerosis, cladribin, fingolimod, fumarate, laquinimod, teriflunamide, monoclonal antibodies.